News | July 28, 2021
Bharat Immunologicals and Biologicals Corporation Q1FY22 net profit at Rs. 1.92 Cr
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Subscribe To Our Newsletter & Stay Updated
